We recently published a list of 10 Firms End Stronger on Tuesday. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other firms that end stronger on Tuesday.

A muted trading persisted on the stock market on Tuesday, with major indices ending in the red, recording minimal losses while digesting President Donald Trump’s tariff policies.

The Dow Jones declined by 0.38 percent, the S&P 500 dipped by 0.17 percent, while the tech-heavy Nasdaq dipped by 0.05 percent.

Ten companies bucked a broader market pessimism, booking modest gains during the session. In this article, we have identified the reasons behind their gains.

To come up with the list, we only considered the stocks with $2 billion market capitalization and $5 million trading volume.

An independent distributor in their pharmacy with a range of biopharmaceutical products on display.

ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics rallied for a third straight day on Tuesday, adding 5.93 percent to end at $22.15 as investor sentiment was buoyed by its business optimism, saying it sees only minimal to no impact from the ongoing trade tensions globally.

In a statement earlier this week, ADMA President and CEO Adam Grossman underscored the company being a fully US-based firm, with manufacturing operations, market sales, and customer engagements conducted exclusively within the US.

“The tariffs that have been implemented on foreign goods, services, and manufacturing should have no impact on ADMA and its supply chain or production operations,” he said.

“Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience, and regulatory compliance but also aligns with increasing federal and private sector preferences for US-made products and services,” he added.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for treating immunodeficient patients at risk for infection and others at risk for certain infectious diseases.

Overall, ADMA ranks 4th on our list of firms that end stronger on Tuesday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.